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A B S T R A C T
The Affordable Care Act (ACA) promised to narrow smoking disparities by expanding access to healthcare and
mandating comprehensive coverage for tobacco treatment starting in 2014. We examined whether two years
after ACA implementation disparities in receiving clinician advice to quit and smokers' knowledge and use of
treatment resources remained.
We conducted telephone interviews in 2016 with a stratified random sample of self-reported smokers newly
enrolled in the Kaiser Permanente Northern California's (KPNC) integrated healthcare delivery system in 2014
(N=491; 50% female; 53% non-white; 6% Spanish language). We used Poisson regression with robust standard
errors to test whether sociodemographics, insurance type, comorbidities, smoking status in 2016 (former, light/
nondaily [< 5 cigarettes per day], daily), and preferred language (English or Spanish) were associated with
receiving clinician advice to quit and knowledge and use of tobacco treatment. We included an interaction
between smoking status and language to test whether the relation between smoking status and key outcomes
varied with preferred language.
Overall, 80% of respondents received clinician advice to quit, 84% knew that KPNC offers cessation coun-
seling, 54% knew that cessation pharmacotherapy is free, 54% used pharmacotherapy, and 6% used counseling.
In multivariate models, Spanish-speaking light/nondaily smokers had significantly lower rates of all outcomes,
while there was no association with other demographic and clinical characteristics.
Following ACA implementation, most smokers newly enrolled in KPNC received clinician advice to quit and
over half used pharmacotherapy, yet counseling utilization was low. Spanish-language outreach efforts and
treatment services are recommended, particularly for adults who are light/nondaily smokers.
1. Introduction
More than two-thirds of smokers want to quit, and more than half
make at least one 24-hour quit attempt annually (Babb et al., 2017;
Clinical Practice Guideline Treating Tobacco Use and Dependence 2000
Update Panel, Liaisons, and Staff, 2008). National guidelines re-
commend that clinicians advise smokers to quit and recommend
smoking cessation counseling and pharmacotherapy, as these inter-
ventions are associated with improved quitting success (Clinical
Practice Guideline Treating Tobacco Use and Dependence 2000 Update
Panel, Liaisons, and Staff, 2008; Stead et al., 2013; Aveyard et al.,
2012). However, groups identified as priorities for tobacco control,
including young adults, racial/ethnic minorities, and low-income in-
dividuals often lack access to or cannot afford appropriate treatments.
As a result, they rarely receive clinician advice to quit smoking
(Browning et al., 2008; Chase et al., 2007; Cokkinides et al., 2008;
Danesh et al., 2014; Houston et al., 2005; Kruger et al., 2012; Lopez-
Quintero et al., 2006; Tran et al., 2010; King et al., 2013) and tend not
to use pharmaceutical aids or cessation counseling (Levinson et al.,
2006; Levinson et al., 2004; Rabius et al., 2004; Murphy et al., 2005).
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Disparities are especially evident among Hispanic/Latino smokers, who
often report interest in utilizing smoking cessation treatment (Cox et al.,
2011; Cupertino et al., 2010), but are less likely than other racial/
ethnic groups to receive advice to quit smoking from a healthcare
professional (Houston et al., 2005; Kruger et al., 2012; Lopez-Quintero
et al., 2006; Tong et al., 2006) and are less likely to use cessation
treatments (Cokkinides et al., 2008; Levinson et al., 2004; Thorndike
et al., 2002). This may because Hispanics/Latinos are overrepresented
among light/nondaily smokers (Zhu et al., 2007; Daza et al., 2006;
Gilpin et al., 1997; Myers et al., 2013; Trinidad et al., 2009), groups
who also tend not to receive clinician advice to quit smoking or use
cessation treatment (Danesh et al., 2014; Tong et al., 2006; Cummings
et al., 1987; Koontz et al., 2004; Owen et al., 1995) despite significant
light smoking-related health risks, including cardiovascular disease,
cancer, respiratory and reproductive diseases and mortality (Schane
et al., 2010).
Health reform holds significant promise for increasing receipt of
clinician advice to quit smoking and improving access to effective to-
bacco treatment for all smokers. The Patient Protection and Affordable
Care Act (ACA) included three provisions important for increasing
smoking cessation among vulnerable populations in 2014: Medicaid
expansion, the implementation of health insurance exchanges, and re-
moval of coverage limits and pre-existing condition exclusions. The
ACA also required comprehensive coverage for tobacco treatments by
most private health plans and for newly eligible Medicaid beneficiaries
(American Lung Association, 2014), covering at least four smoking
cessation counseling sessions and 90 days of FDA-approved tobacco
cessation pharmacotherapies. The law prohibited cost-sharing and prior
authorization restrictions for tobacco cessation pharmacotherapy be-
ginning in 2014 (Centers for Medicare and Medicaid Services, 2014).
Whether the ACA succeeds in reducing disparities in tobacco treat-
ment utilization depends on the extent to which clinicians provide advice
to quit smoking equitably to all smokers and whether priority popula-
tions utilize tobacco treatments at equal rates. Recent US data show that
the percentage of adult smokers who reported receiving advice to quit
from a health professional increased from 2010 to 2015. However, per-
sistent inequalities in receiving cessation advice among light/non-daily
smokers, Hispanics/Latinos, young adults, low-income adults, and un-
insured smokers remained (Tan et al., 2018). Further, 30-day smoking
prevalence declined and pharmacotherapy fills increased in states that
expanded Medicaid (Young-Wolff et al., 2018; Simon et al., 2017;
MacLean et al., 2017). Our prior work with smokers enrolled in Cali-
fornia exchange or non-exchange commercial plans found that the ACA's
elimination of pharmacotherapy copayments was associated with a small
increase in pharmacotherapy prescription fills with a greater effect
among lower-income smokers (Young-Wolff et al., 2018).
This study adds to prior work by examining whether vulnerable
subgroups of smokers enrolled in healthcare in the post-ACA era are less
likely than other groups to receive clinician advice to quit smoking or to
know about and use tobacco treatment. In addition, because the ACA
resulted in significant gains in healthcare coverage for Spanish speakers
with limited English proficiency in California (The Henry J. Kaiser
Family Foundation, 2013), and Spanish-speaking Hispanics/Latinos are
more likely to be light smokers than English-speaking Hispanics/Latinos
(Palinkas et al., 1993), we tested for an interaction between language
and smoking frequency to examine whether the association of smoking
status and key outcomes varied by Spanish versus English speakers.
2. Methods
2.1. Setting
The study was based in Kaiser Permanente Northern California
(KPNC), an integrated healthcare system providing comprehensive
health services to> 4 million members (Kaiser Permanente, 2018).
KPNC membership is diverse and representative of the population
living in its geographic area (Selby et al., 2005). The study was ap-
proved by the KPNC Institutional Review Board.
KPNC prioritizes smoking cessation (Goldstein et al., 2005) and
provides cessation counseling in Spanish to serve the ~5% of KPNC
members who prefer to speak Spanish. While most Medicaid smokers
already had zero cost-sharing for FDA-approved smoking cessation
pharmacotherapy in 2014, KPNC eliminated cost-sharing for all mem-
bers with ACA-compliant plans on January 1, 2015, following national
guidance issued in May 2014 (Centers for Medicare and Medicaid
Services, 2014).
2.2. Sample
In 2016 we conducted a telephone survey of KPNC members newly
enrolled in KPNC in the first six months of 2014 and identified through
the electronic health record (EHR) as current smokers in the six months
following enrollment. KPNC members are routinely screened for
smoking at outpatient appointments by medical assistants. The survey
was part of a larger study on the impact of the ACA on smoking and
tobacco treatment utilization (Young-Wolff et al., 2017) and assessed
patients' experiences since joining KPNC in 2014, a period which in-
cluded the elimination of pharmacotherapy copayments in 2015.
Participants included “current smokers” enrolled in KPNC in 2014
through a Medicaid, California exchange, or non-exchange commercial
plan, who had not been KPNC members in the 12-months prior to en-
rollment. Inclusion also required English or Spanish primary language
and active KPNC membership in 2016. To increase statistical power
with underrepresented groups, we oversampled smokers who obtained
coverage through the California exchange or Medicaid and those with
preferred to speak Spanish, given research indicating low pharma-
cotherapy use among Hispanic/Latino smokers (Young-Wolff et al.,
2017). We selected and contacted patients in eleven waves using simple
random sampling within language-insurance categories. Patients were
assigned sample weights that were inversely proportional to the prob-
ability of selection within their language-insurance strata.
Eligible patients were mailed letters that included an explanation of
the survey, a notice that they would be called in two weeks, and a toll-
free number to call for more information or to decline participation.
Patients were called between August 29, 2016 and December 30, 2016,
by a trained interviewer who further explained the project, obtained
verbal consent, and completed the ~20-minute telephone survey in
English or Spanish. Of the 1114 eligible patients, 96 (9%) could not be
located due to incorrect address and phone number, 327 (29%) did not
respond to telephone calls, 3 were too ill to participate, and 178 (17%)
declined participation or did not complete the survey. The response rate
among contacted patients was 50%, yielding 509 completed surveys. Of
those, 17 who indicated they were not smokers at the time of enroll-
ment in 2014, and one patient missing income were excluded. A total of
491 surveys were included in this analysis. Spanish-speaking (70%) and
Hispanic/Latino patients (62%) were more likely to complete the
survey than English-speaking (45%) and non-Hispanic/Latino patients
(45%) (χ2 ps < .001); there were no differences in completion by other
demographics.
2.3. Patient characteristics
We included tobacco-related questions on the survey and linked
patients' demographic data (age, gender, race/ethnicity, median
neighborhood household income, language, and insurance) from the
EHR. We included the number of KPNC outpatient visits between 2014
and survey completion in 2016 (0–5, 6–10, 11–24, 25+), and co-
morbidities identified via International Classification of Diseases, Ninth
Revision and Tenth Revision codes from the EHR: psychiatric disorders
(depression, anxiety, attention deficit hyperactivity, bipolar spectrum,
and psychotic disorders), substance use disorders (drug and alcohol use
disorders), and medical conditions (arthritis, hypertension, chronic
K.C. Young-Wolff, et al. Preventive Medicine Reports 14 (2019) 100847
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pain, diabetes, asthma, heart disease, and chronic obstructive pul-
monary disease).
2.4. Smoking status
Among identified smokers in 2014 from EHR data (see Sample
section), smoking status in 2016 was categorized as “daily”, “light/
nondaily”, or “former” using two questions from the survey: “Do you
currently smoke cigarettes?” (every day, some days, not at all) and
“How many cigarettes do you usually smoke per day, on the days that
you smoke?” Patients who indicated that they smoked ≥five cigarettes
every day were categorized as daily smokers. Patients who smoked
some days or<five cigarettes every day were categorized as light/
nondaily smokers. Patients who indicated that they smoked “not at all”
were considered former smokers.
2.5. Outcomes
All outcomes were categorized as “Yes” or “No” based on 2016
survey responses concerning patients' experiences since joining KPNC in
2014. Receipt of clinician advice to quit smoking was determined from
the question, “Since joining Kaiser in 2014, has a healthcare clinician
talked with you about quitting smoking cigarettes?” Knowledge of
smoking cessation counseling/classes based on answering yes to either
of the following questions: “Do you know that local Kaiser facilities
offer in-person groups to help people quit smoking?” and “Do you know
that Kaiser offers personal telephone counseling to help people quit
smoking?” Patient use of cessation classes/counseling was determined
Table 1
Characteristics and weighted proportions of newly enrolled health plan members who had knowledge of or used tobacco cessation treatmentsa.
Patient
characteristics, N
(weighted column %)
Knowledge or use of tobacco cessation treatments, N (weighted row %)
Clinician
advised
quitting
p valueb Patient knew
about
counseling/
classes
p valueb Patient knew
pharmacotherapy was
free
p valueb Patient used
pharmacotherapy
p valueb
Overall 491 (100) 376 (80) 396 (84) 237 (54) 233 (54)
Gender .08 .14 .59 .01
Female 242 (50) 195 (85) 204 (87) 120 (55) 126 (62)
Male 249 (50) 181 (75) 192 (80) 117 (52) 107 (46)
Age .26 .56 .23 .09
18–25 33 (7) 23 (80) 24 (81) 16 (46) 10 (35)
25–35 116 (31) 89 (73) 95 (79) 50 (43) 49 (45)
35–45 107 (20) 76 (79) 85 (86) 52 (61) 52 (54)
45–55 137 (23) 105 (82) 106 (82) 66 (59) 69 (62)
55+ 98 (19) 83 (89) 86 (90) 53 (59) 53 (64)
Race/ethnicity .14 .16 .06 < .001
Non-Hispanic white 195 (47) 155 (78) 163 (82) 117 (61) 127 (68)
Hispanic 165 (18) 111 (73) 121 (76) 50 (38) 47 (31)
Black 63 (15) 54 (91) 54 (91) 35 (56) 29 (49)
Other/unknown 68 (19) 56 (82) 58 (88) 35 (48) 30 (45)
Insurance .20 .23 .23 .39
California exchange 161 (24) 128 (86) 134 (89) 78 (60) 74 (57)
Non-exchange commercial 164 (62) 125 (78) 133 (83) 75 (50) 67 (51)
Medicaid 166 (14) 123 (77) 129 (79) 84 (57) 92 (60)
Median household income .92 .58 .01 .10
<$40 K 141 (29) 110 (78) 112 (80) 66 (44) 64 (43)
$40 K–60 K 174 (30) 132 (80) 143 (86) 81 (47) 86 (57)
>$60 K 176 (41) 134 (81) 141 (85) 90 (65) 83 (60)
Any psychiatric disorder .76 .70 .31 .18
Yes 107 (19) 85 (82) 91 (86) 61 (60) 64 (63)
No 384 (81) 291 (79) 305 (83) 176 (52) 169 (52)
Substance use disorder .13 .02 .19 .11
Yes 34 (8) 30 (90) 32 (97) 22 (68) 24 (72)
No 457 (92) 346 (79) 364 (82) 215 (52) 209 (52)
Any medical comorbidity .46 .34 .29 .05
Yes 255 (47) 198 (82) 208 (86) 127 (57) 136 (61)
No 236 (53) 178 (78) 188 (82) 110 (50) 97 (48)
Number of outpatient visits
between joining KPNC
in 2014 and completing
the survey in 2016
.41 .50 .50 .04
0–5 89 (17) 60 (75) 67 (85) 39 (55) 29 (43)
6–10 118 (26) 91 (75) 97 (78) 56 (45) 49 (48)
11–25 168 (35) 125 (81) 131 (84) 79 (57) 80 (54)
>25 116 (22) 100 (87) 101 (88) 63 (57) 75 (70)
Preferred language < .001 .005 < .001 < .001
English 368 (94) 300 (81) 310 (85) 210 (55) 206 (56)
Spanish 123 (6) 76 (59) 86 (68) 27 (27) 27 (23)
2016 smoking status .41 .70 .85 .01
Daily 200 (44) 165 (83) 172 (86) 107 (55) 124 (65)
Light/nondaily 125 (19) 84 (80) 89 (82) 42 (50) 36 (39)
Quit 166 (37) 127 (76) 135 (82) 88 (54) 73 (49)
Abbreviation: KPNC=Kaiser Permanente Northern California.
a Unweighted frequencies and weighted percentages.
b p values from Rao-Scott χ2 tests of independence.
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from the question, “Since joining Kaiser, which of the following
methods/resources have you used to help you quit smoking cigarettes?
[check all that apply]”. Patients who affirmed “Kaiser health education
class for quitting smoking” or “Kaiser telephone wellness coaching for
quitting smoking” were considered to have used counseling/classes.
Patient knowledge that pharmacotherapy was free was derived from
the question, “Do you know that medications to help people quit
smoking (for example, the nicotine patch) are free for most Kaiser
members if they're prescribed by your doctor and filled at a Kaiser
pharmacy?” Finally, pharmacotherapy use was determined from the
question, “For quitting smoking have you used: nicotine gum, nicotine
patch, nicotine nasal spray, nicotine inhaler, nicotine lozenge, bupro-
pion (e.g., Zyban, Wellbutrin), varenicline or Chantix?” This question
was asked of all respondents even though pharmacotherapy may not be
indicated for patients who smoke<10 cigarettes a day and includes
pharmacotherapy from a source other than a KPNC pharmacy.
2.6. Statistical analysis
We first determined unweighted frequencies and weighted percen-
tages of the survey respondents' baseline characteristics using normal-
ized sample weights. Next, we examined the unweighted frequencies
and weighted percentages for each outcome for the overall sample and
for each level of the baseline characteristics. We used Rao-Scott χ2 tests
to examine the association between outcomes and patient character-
istics (Rao and Scott, 1981). To examine outcomes by language and
smoking status, we combined the language and smoking status vari-
ables to form a six-level variable (English-speaking daily smoker, Eng-
lish-speaking light/nondaily smoker, English-speaking former smoker,
Spanish-speaking daily smoker, Spanish-speaking light/nondaily
smoker, and Spanish-speaking former smoker) and present the
weighted percentages.
We report the relative risks (RRs) of each outcome adjusted for
gender, age, race/ethnicity, insurance type, income, any psychiatric
disorder, substance use disorder, medical comorbidity, language,
smoking status, outpatient visits, and the interaction of language and
smoking status, as defined above. We used a modified Poisson regres-
sion approach with robust error variance (Zou, 2004), which provides a
direct assessment of the RRs along with the 95% CIs. To account for the
sampling design, we adopted a model-based strategy that does not use
the weights but includes key covariates including the variables used to
construct the sample weights (Winship and Radbill, 1994). Analyses
were performed using SAS software, version 9.4 (SAS Institute, Inc.).
3. Results
The 491 respondents were 50% male; 47% non-Hispanic white, 18%
Hispanic, 15% black, and 19% other or unknown race/ethnicity. Six
percent completed the survey in Spanish and 94% in English (Table 1).
Respondents were 44% daily smokers, 19% light/nondaily smokers (4%
light, 15% nondaily), and 37% had quit smoking between the time of
enrollment (2014) and the time of the 2016 survey (i.e., former smo-
kers). By the combined language and smoking status strata, respondents
were 42% English-speaking daily smokers, 17% English-speaking light/
nondaily smokers, 35% English-speaking former smokers, 2% Spanish-
speaking daily smokers, 3% Spanish-speaking light/nondaily smokers,
and 2% Spanish-speaking former smokers (Fig. 1).
Overall, 80% of patients reported that their clinician had advised
them to quit smoking, 54% knew pharmacotherapy was free, and 54%
had used pharmacotherapy (Table 1). While 84% of patients knew KPNC
offered cessation counseling, only 6% had used these services. In bi-
variate comparisons, Spanish-speakers and those without a substance use
disorder were less likely to know about cessation counseling/classes.
Patients with lower income and Spanish-speakers were less likely to
know that pharmacotherapy was free at KPNC pharmacies, and males,
patients with Hispanic, black or other/unknown race/ethnicity, Spanish-
speakers, and light/nondaily smokers were less likely to have used
pharmacotherapy. Due to the small number of patients who used coun-
seling/classes (n=20), the bivariate comparisons resulted in small cell
counts and were suppressed from Table 1 for privacy concerns.
Next, we stratified outcomes by language and smoking status.
Relative to English-speaking patients regardless of smoking status and
Spanish-speaking daily smokers, Spanish-speaking patients who were
light/nondaily or former smokers were less likely to report that their
clinician had advised them to quit (55% vs. 70%–84%), less likely to
know about cessation counseling/classes (61–65% vs. 83%–86%), less
likely to use cessation counseling/classes (0% vs. 5%–7%), less likely to
know that pharmacotherapy is free (17%–24% vs. 48%–55%), and less
likely to have used pharmacotherapy (11%–15% vs. 44%–65%) (Fig. 1).
The adjusted relative risks (aRRs) for each outcome from multi-
variate models that included an interaction between language and
smoking status are presented in Table 2. Patient use of counseling/
classes was not modeled due to low overall prevalence (6%) and the
lack of use by Spanish-speaking light/nondaily or former smokers
(Fig. 1). While the interaction of language and smoking status was only
statistically significant for knowledge that pharmacotherapy was free
(p= .03) and use of pharmacotherapy (p= .006), there were sig-
nificant differences between language-smoking status strata for all four
outcomes. Spanish-speaking light/nondaily smokers were less likely to
receive clinician advice to quit than other groups. English-speaking
smokers (daily, aRR=1.55, 95%CI=1.16–2.06; light/nondaily,
aRR=1.39, 95%CI=1.03–1.90; and former, aRR=1.51,
95%CI=1.14–2.01) were more likely to receive clinician advice to quit
compared to Spanish-speaking light/nondaily smokers. Spanish-
speaking light/nondaily smokers were also less likely to know about
counseling/classes. English-speaking daily smokers (aRR=1.37,
95%CI=1.06–1.77) and former smokers (aRR=1.36,
95%CI=1.06–1.76), and Spanish-speaking daily smokers
(aRR=1.34, 95%CI= 1.02–1.75) were more likely to know about
counseling/classes compared to Spanish-speaking light/nondaily smo-
kers.
Spanish-speaking light/nondaily smokers were less likely to know
pharmacotherapy was free and less likely to use pharmacotherapy
compared to other categories of smokers. English-speaking smokers
(daily, aRR=4.67, 95%CI= 2.06–10.58; light/nondaily, aRR=4.15,
95%CI=1.79–9.58; former, aRR=5.33, 95%CI=2.36–12.05), and
Spanish-speaking daily smokers (aRR=3.14, 95%CI= 1.31–7.55)
were more likely to know that pharmacotherapy was free compared to
Spanish-speaking light/nondaily smokers. English-speaking smokers
(daily, aRR=7.09, 95%CI= 2.55–19.70; light/nondaily, aRR=5.15,
95%CI=1.79–14.80; former, aRR=5.66, 95%CI=2.02–15.81), and
Spanish-speaking daily smokers (aRR=6.03, 95%CI= 2.21–16.48)
were more likely to use pharmacotherapy than Spanish-speaking light/
nondaily smokers.
A few demographic or clinical characteristics were marginally asso-
ciated with the outcomes. Clinician advice to quit was higher among
black patients (aRR=1.15, 95%CI=1.00–1.32), patients with in-
surance through the California exchange (vs. those with Medicaid,
aRR=1.14, 95%CI=1.00–1.29), and patients with>25 outpatient
visits (vs. ≤5, aRR 1.21, 95% CI=1.01–1.45). Knowledge of coun-
seling/classes was higher among patients with versus without a sub-
stance use disorder (aRR=1.12, 95%CI=1.00–1.26). Use of pharma-
cotherapy was higher among adults aged 45–54 than those aged 18–24
(aRR=1.77, 95%CI=1.05–2.97) and patients with>25 outpatient
visits relative to those ≤5 visits (aRR 1.50, 95%CI=1.07–2.09).
4. Discussion
This study of disparities in receiving clinician advice to quit
smoking and knowledge and use of tobacco treatment among insured
smokers with easy access to tobacco treatments post-ACA im-
plementation has three key findings. First, most smokers were advised
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to quit smoking by their healthcare provider and over half knew that
pharmacotherapy was free and used it, yet use of cessation counseling/
classes was low. Smoking cessation counseling is strongly associated
with improved quitting success (Clinical Practice Guideline Treating
Tobacco Use and Dependence 2000 Update Panel, Liaisons, and Staff,
2008) and the low usage of counseling among smokers in our study is
concerning. Strategies to increase patient use of free cessation coun-
seling are needed, including outreach to patients (e.g., via secure
messages) and provider referrals and linkages to counseling services.
Second, Spanish-speakers who were light/nondaily smokers or former
smokers reported the lowest receipt of clinician advice to quit smoking,
lowest awareness of free pharmacotherapy and counseling/classes, and
lowest use of counseling/classes and pharmacotherapy. Third, ac-
counting for language and light/non-daily smoking, there were few
differences in receipt of quit smoking advice, knowledge of smoking
cessation classes/counseling and free pharmacotherapy, or use of ces-
sation treatments by age, race/ethnicity, insurance coverage, or median
household income, suggesting that healthcare reform may have helped
to equalize access to and use of tobacco treatments for many at-risk
groups. These findings differ from our prior study of non-Medicaid
patients, which found lower knowledge about free cessation pharma-
cotherapy among lower income commercially insured patients (Young-
Wolff et al., 2018), suggesting that Medicaid patients may have greater
awareness that pharmacotherapy is free than commercially insured
patients.
While smoking prevalence continues to decrease in the US, the
proportion of light/nondaily smokers has increased (Substance Abuse
and Mental Health Services Administration, 2018; Jamal et al., 2016),
and in California, most Hispanic/Latino smokers are light smokers (Zhu
et al., 2007). Compared to heavier smokers, light smokers experience
fewer symptoms of nicotine withdrawal (Shiffman et al., 1994), are
more likely to quit without cessation interventions (Mikkelsen et al.,
2015), and do not consider themselves to be at risk for smoking-related
diseases (Ayanian and Cleary, 1999; Hamilton et al., 2000). Yet, light
smoking is not associated with greater quitting success among Spanish-
speaking Hispanic/Latino smokers (Reitzel et al., 2009; Hayes and
Borrelli, 2013). Thus disparities in receiving advice and lower aware-
ness of cessation treatments among Spanish-speaking light/nondaily
smokers is a significant issue given the adverse health effects associated
with light and nondaily smoking (Schane et al., 2010). Although
pharmacotherapy is not indicated for light/nondaily smokers (although
some evidence suggests that light smokers benefit from use of nicotine
lozenge and gum) (Shiffman et al., 2002; Shiffman, 2005; Krupski et al.,
2013), there is strong clinical evidence that quitting smoking is bene-
ficial for this group. Additional research is needed to explore factors
underlying these disparities among Spanish-speakers, which could be
due to language barriers, provider discrimination, patient denial or
mistrust of medicine or clinicians, and differential recall of clinician
advice among Spanish-speakers (Levinson et al., 2004). Beyond the
health benefits, providing consistent clinician smoking cessation advice
to Spanish-speaking light/nondaily smokers may have the added ben-
efit of enhancing patient satisfaction, as smokers who talk to their
healthcare providers about quitting during clinical visits report greater
satisfaction with their care (Winpenny et al., 2017; Solberg et al., 2001;
Barzilai et al., 2001; Holla et al., 2018).
Our analyses adjusted for Hispanic ethnicity, and findings suggest
that commonly identified ethnic disparities in receiving advice to quit
smoking and using cessation treatments may be explained in part by
language barriers and the higher prevalence of light smoking among
Spanish-speaking populations. This is consistent with prior research
indicating that disparities in physician advice to quit among Hispanics/
Latinos are reduced after accounting for health status and light smoking
(Levinson et al., 2004). Among Hispanics/Latinos, smokers with less
acculturation are more likely to be light smokers (Rodriquez et al.,
2015), and future studies should tease apart effects of preferred lan-
guage versus acculturation. If Spanish-speakers are less likely to receive
advice to quit smoking, it is possible that other prevention messages
also are not being delivered. The extent to which Spanish-speakers are
English-speaking
daily smokers
English-speaking 
light/nondaily smokers
English-speaking 
former smokers
Spanish-speaking 
daily smokers
Spanish-speaking 
light/nondaily smokers
Spanish-speaking 
former smokers
84%
84%
77%
70%
55%
55%
86%
85%
83%
83%
61%
65%
6%
5%
7%
7%
0%
0%
55%
55%
55%
48%
17%
24%
65%
44%
51%
53%
11%
15%
P-value of χ2
associa"on of outcome
and language-smoking 
status strata:                         .05 .21 NA .11 <.001
Clinician advised 
qui#ng
Pa"ent knew 
pharmacoptherapy 
was free
Pa"ent knew about 
counseling/classes
Pa"ent used 
counseling/classes
Pa"ent used 
pharmacotherapy
Fig. 1. Knowledge or use of tobacco cessation treatments by preferred language-smoking status strata.
Note: percentages in the figure are weighted; the unweighted frequencies and weighted percentages of the overall cohort for each of the language-smoking status
strata are as follows: English-speaking daily smokers: 167 (42%), English-speaking light/nondaily smokers: 74 (17%), English-speaking former smokers: 127 (35%),
Spanish-speaking daily smokers: 33 (2%), Spanish-speaking light/nondaily smokers: 51 (3%), Spanish-speaking former smokers: 39 (2%).
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affected by other disparities in health services access and preventive
care is unclear. Some research suggests that while the ACA helped to
reduce disparities in healthcare access and utilization among English-
speaking Hispanics/Latinos, disparities among Spanish-speakers re-
mained (Alcala et al., 2017).
While KPNC clinical visits and smoking cessation classes and
counseling are available in Spanish, results from this study suggest that
additional work is needed to engage Spanish-speaking light/nondaily
smokers in cessation treatment. This could include Spanish-language
outreach efforts and consistent clinician advice to quit, education for
Spanish-speakers about the harms of light/nondaily smoking, and cul-
turally sensitive smoking cessation interventions for Spanish-speaking
light/nondaily smokers. Further, because light smokers tend to mini-
mize their own smoking risks, messages focused on the harms of sec-
ondhand smoke exposure may be more effective in helping them quit
smoking than messages focused on personal health risks (Tong et al.,
2006; Schane et al., 2013; Schane and Glantz, 2008). This may be
especially important because Latino light daily smokers are less likely
than Latino heavy daily smokers to believe that their smoking may
negatively affect their children's health (Hayes and Borrelli, 2013),
suggesting that Spanish-language outreach that highlights the harms of
secondhand smoke associated with light smoking may be particularly
effective.
4.1. Limitations
This study has several limitations. Our survey was limited to self-
reported data in 2016 among smokers newly enrolled in KPNC in 2014,
and findings may not be generalizable to uninsured smokers or those
who have been enrolled in KPNC for longer periods of time. Cost-
sharing for pharmacotherapy was eliminated in KPNC in 2015 for most
patients, and we are not able to differentiate whether use of pharma-
cotherapy occurred before versus after cost-sharing elimination.
Further, consistent with national surveys on behavioral risk factors
(Substance Abuse and Mental Health Services Administration, 2018;
Centers for Disease Control and Prevention, 2017), our survey response
rate was 50%; however, while English-speaking and non-Hispanic pa-
tients were less likely to complete the survey than Spanish-speaking and
Hispanic patients, there were no other demographic differences in
survey completion rates. Outcomes were not measured prior to en-
rollment in KPNC, so we cannot evaluate changes over time in patient
receipt of clinician advice to quit smoking, or knowledge or use of to-
bacco cessation interventions. The survey assessed patient use of KPNC
smoking cessation counseling/classes and may have underestimated
patients' use of services. Our smoking status variables are self-reported,
which may result in misclassification of quitting. Our sample size did
not allow us to look at light and non-daily smokers separately. How-
ever, cessation pharmacotherapy is not recommended for nondaily and
very light smokers, and we anticipate similar challenges in engaging
these types of smokers into counseling because of low perceived harm
relative to daily and moderate/heavy smokers.
5. Conclusions
Clinician advice to quit smoking and patient use of smoking cessa-
tion interventions are associated with improved quitting success (Stead
et al., 2013; Aveyard et al., 2012) and the ACA holds promise to narrow
disparities in smoking cessation by equalizing access to effective
treatments. Our findings suggest that following ACA implementation,
most self-reported smokers newly enrolled in KPNC were advised to
quit by their healthcare provider and over half used pharmacotherapy,
yet counseling was underutilized. We did not find disparities related to
clinician advice or patient use or knowledge of tobacco control services
by race/ethnicity, age, gender or income; however, we did find that
Spanish-speaking light smokers were less likely than other groups to
receive advice to quit and had lower knowledge and use of cessation
treatments, suggesting missed intervention opportunities. To maximize
the potential benefit of the ACA on tobacco control, clinicians should
provide Spanish-language advice to quit and tailor outreach efforts to
enhance access and extend treatment services to Spanish-speaking
adults who are light or nondaily smokers.
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